ProfileGDS4814 / ILMN_2174804
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 27% 49% 55% 45% 42% 61% 53% 53% 58% 57% 58% 58% 59% 45% 43% 51% 56% 50% 58% 55% 47% 49% 56% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)45.013427
GSM780708Untreated after 4 days (C2_1)50.238649
GSM780709Untreated after 4 days (C3_1)52.546355
GSM780719Untreated after 4 days (C1_2)49.090845
GSM780720Untreated after 4 days (C2_2)48.25542
GSM780721Untreated after 4 days (C3_2)56.131361
GSM780710Trastuzumab treated after 4 days (T1_1)51.500853
GSM780711Trastuzumab treated after 4 days (T2_1)51.724553
GSM780712Trastuzumab treated after 4 days (T3_1)54.099358
GSM780722Trastuzumab treated after 4 days (T1_2)53.692857
GSM780723Trastuzumab treated after 4 days (T2_2)53.798158
GSM780724Trastuzumab treated after 4 days (T3_2)54.295358
GSM780713Pertuzumab treated after 4 days (P1_1)54.557459
GSM780714Pertuzumab treated after 4 days (P2_1)48.863745
GSM780715Pertuzumab treated after 4 days (P3_1)48.506843
GSM780725Pertuzumab treated after 4 days (P1_2)50.716451
GSM780726Pertuzumab treated after 4 days (P2_2)52.961756
GSM780727Pertuzumab treated after 4 days (P3_2)50.614850
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)54.121558
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)52.538455
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)49.549447
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)50.293349
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)52.878356